Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories cEO Pay Ratio Determination Date (Oct 1) Non-U.S. Employees
Form DEF 14A Proxy Statement (CEO Pay Ratio Disclosure)
Latest, FY2025
78,140
Period ended Dec 31, 2025
Change on a year earlier
+0.7%
77,563 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CEO Pay Ratio Determination Date (Oct 1) Non-U.S. Employees | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 78,140 | +0.7% | SEC Filing (0001308179-26-000064) ↗ |
| FY2024 | Dec 31, 2024 | 77,563 | -0.3% | SEC Filing (0001308179-25-000134) ↗ |
| FY2023 | Dec 31, 2023 | 77,791 | -0.7% | SEC Filing (0001308179-24-000182) ↗ |
| FY2022 | Dec 31, 2022 | 78,378 | +1.8% | SEC Filing (0001308179-23-000247) ↗ |
| FY2021 | Dec 31, 2021 | 76,973 | +3.3% | SEC Filing (0001206774-22-000778) ↗ |
| FY2020 | Dec 31, 2020 | 74,532 | – | SEC Filing (0001047469-21-000592) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories CEO Pay Ratio Determination Date (Oct 1) Non-U.S. Employees, annual FY2020–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/emp-oct1-non-us
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.